Immunotherapy / IL-2 agonistPhase 3 trialInvestigational
Bempegaldesleukin
How it works
Stimulates the production of IL-2, a protein that helps activate immune cells to attack cancer cells.
Cancer types
Melanoma— All patients
Efficacy
In clinical trials, bempegaldesleukin improved response rates in patients with advanced melanoma, with a response rate of approximately 44%.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.